S Gilbody1, P Wilson, I Watt. 1. Department of Health Sciences, Seebohm Rowntree Building, Alcuin College, University of York YO10 5DD. sg519@york.ac.uk
Abstract
BACKGROUND: Direct to consumer advertising is increasingly used by the pharmaceutical industry, but its benefits and harms have yet to be summarised in a comprehensive and rigorous manner. METHODS: A systematic review was conducted of robust evaluations of the impact (positive and negative) of direct to consumer advertising. A broad range of databases and data sources (including Cinahl, Embase, HMIC, HSRProj, Medline, PsycInfo, and the internet) were searched from inception to 2004. RESULTS: From 2853 citations only four reports were found that met the strict inclusion criteria and provided usable results. Direct to consumer advertising is associated with increased prescription of advertised products and there is substantial impact on patients' request for specific drugs and physicians' confidence in prescribing. No additional benefits in terms of health outcomes were demonstrated. DISCUSSION: Direct to consumer advertising is banned in most countries, and the research evidence tends to support the negative impact that is feared by those who support a legislative ban. Further research is needed into the clinical and economic impact of direct to consumer advertising in healthcare systems.
BACKGROUND: Direct to consumer advertising is increasingly used by the pharmaceutical industry, but its benefits and harms have yet to be summarised in a comprehensive and rigorous manner. METHODS: A systematic review was conducted of robust evaluations of the impact (positive and negative) of direct to consumer advertising. A broad range of databases and data sources (including Cinahl, Embase, HMIC, HSRProj, Medline, PsycInfo, and the internet) were searched from inception to 2004. RESULTS: From 2853 citations only four reports were found that met the strict inclusion criteria and provided usable results. Direct to consumer advertising is associated with increased prescription of advertised products and there is substantial impact on patients' request for specific drugs and physicians' confidence in prescribing. No additional benefits in terms of health outcomes were demonstrated. DISCUSSION: Direct to consumer advertising is banned in most countries, and the research evidence tends to support the negative impact that is feared by those who support a legislative ban. Further research is needed into the clinical and economic impact of direct to consumer advertising in healthcare systems.
Authors: Barbara Mintzes; Morris L Barer; Richard L Kravitz; Arminée Kazanjian; Ken Bassett; Joel Lexchin; Robert G Evans; Richard Pan; Stephen A Marion Journal: BMJ Date: 2002-02-02
Authors: Meredith B Rosenthal; Ernst R Berndt; Julie M Donohue; Richard G Frank; Arnold M Epstein Journal: N Engl J Med Date: 2002-02-14 Impact factor: 91.245
Authors: Joel S Weissman; David Blumenthal; Alvin J Silk; Michael Newman; Kinga Zapert; Robert Leitman; Sandra Feibelmann Journal: Health Aff (Millwood) Date: 2004 Jan-Jun Impact factor: 6.301
Authors: Barbara Mintzes; Morris L Barer; Richard L Kravitz; Ken Bassett; Joel Lexchin; Arminée Kazanjian; Robert G Evans; Richard Pan; Stephen A Marion Journal: CMAJ Date: 2003-09-02 Impact factor: 8.262
Authors: Matthew Daubresse; Susan Hutfless; Yoonsang Kim; Rachel Kornfield; Dima M Qato; Jidong Huang; Kay Miller; Sherry L Emery; G Caleb Alexander Journal: Am J Respir Crit Care Med Date: 2015-07-01 Impact factor: 21.405
Authors: K A B Goddard; J Robitaille; N F Dowling; A R Parrado; J Fishman; L A Bradley; C A Moore; M J Khoury Journal: Public Health Genomics Date: 2008-11-26 Impact factor: 2.000
Authors: Spencer D Dorn; Joel F Farley; Richard A Hansen; Nilay D Shah; Robert S Sandler Journal: Gastroenterology Date: 2009-05-13 Impact factor: 22.682